Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $27.02 and traded as high as $33.71. Assembly Biosciences shares last traded at $31.74, with a volume of 110,684 shares.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research note on Thursday, November 20th. Citigroup initiated coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They issued an “outperform” rating for the company. Finally, Citizens Jmp initiated coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Assembly Biosciences presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Trading Up 0.6%

The stock’s 50-day simple moving average is $34.36 and its 200-day simple moving average is $27.02. The stock has a market cap of $502.13 million, a price-to-earnings ratio of -6.63 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The business had revenue of $10.79 million during the quarter, compared to analyst estimates of $7.46 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. On average, equities research analysts forecast that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the period. Palumbo Wealth Management LLC increased its holdings in Assembly Biosciences by 3.8% in the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC raised its position in shares of Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 3,312 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in shares of Assembly Biosciences during the 3rd quarter worth approximately $852,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares during the period. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.